Nonvenereal Syphilis Treatment Market Outlook:
Nonvenereal Syphilis Treatment Market size was over USD 381.03 million in 2025 and is projected to reach USD 893.8 million by 2035, growing at around 8.9% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of nonvenereal syphilis treatment is assessed at USD 411.55 million.
The growth of the market can be attributed to the improving coverage and accuracy of nonvenereal syphilis testing worldwide as well as the development of a novel rapid, point-of-care test (POCT) for confirmatory testing of active syphilis infection with the rising concern about the globally increasing transmission of bejel, especially among children living in tropical, subtropical, or warm arid climates, predominantly by direct contact. As per the World Health Organization data, more than 80,000 cases of bejel are reported every year worldwide.
Nonvenereal syphilis is an infectious disease common in some parts but rare in many parts of the world. The bejel infection is very similar to syphilis but its means of transmission typically comprises non-sexual skin contact or the common use of eating and drinking utensils against that of syphilis that is sexually transmitted. Concern about the spreading spiral bacteria of the genus Treponema has led to the increasing effort taken by governments as well as healthcare professionals worldwide to develop accurate diagnostic tools for the identification of infections caused by T. pallidum subspecies so that their treatments can be developed accordingly, which is expected to bring in revenue boost for the key market players in the nonvenereal syphilis treatment market.
